Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
Date:2/12/2008

s and Stockholders' Equity

Current liabilities:

Notes payable and current maturities

of long-term debt $331.3 $189.0

Accounts payable 131.0 97.2

Accrued payroll and payroll taxes 55.0 47.4

Accrued income taxes 47.1 48.6

Other accrued expenses 70.6 60.4

Total current liabilities 635.0 442.6

Long-term debt 207.0 337.9

Deferred post-retirement benefits 36.9 38.5

Deferred taxes 42.3 48.1

Other liabilities 91.3 56.3

Total liabilities 1,012.5 923.4

Stockholders' equity:

Common stock 201.8 201.8

Capital in excess of par value 109.7 79.1

Common stock in treasury (1,534.1) (1,375.4)

Retained earnings 2,679.3 2,424.7

Accumulated other comprehensive income 159.9 80.7

Total stockholders' equity 1,616.6 1,410.9

Total liabilities and stockholders' equity $2,629.1 $2,334.3

SIGMA-ALDRICH CORPORATION

Consolidated Statements of Cash Flows (Unaudited)

(in millions)

Twelve Months

Ended December 31,

2007 2006

Cash flows from operating activities:

Net income
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for ... that are able to enter fat cells, inhibiting the formation of new fat. ...
Breaking Biology Technology:Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... Delaware has won a $4.4 million grant from ... Agency (ARPA-E) to lead a multidisciplinary, multi-institutional research ... permanent magnets. Stronger magnets are essential for ... technology, and communications systems in the 21st-century, and ...
... VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... announce third quarter financial results after the market closes ... conference call and live webcast at 4:30 p.m. ET ... the third quarter results. , A live webcast will ...
... Corporation (Nasdaq: DNDN ) today announced that it ... Application (BLA) for PROVENGE ® (sipuleucel-T), the Company,s ... Administration (FDA). Dendreon is seeking licensure for PROVENGE ... If approved by the FDA, PROVENGE would represent the ...
Cached Biology Technology:UD wins $4.4 million to develop next-generation magnets 2OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results 2Dendreon Completes Submission of Biologics License Application for PROVENGE 2Dendreon Completes Submission of Biologics License Application for PROVENGE 3
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... French . , Quebec City, April 15, 2010Researchers ... Center have proven that it is possible to repair the ... by Professor Jacques P. Tremblay, is presenting its new therapeutic ... of the scientific journal Gene Therapy . Duchenne ...
... research team has tested the utility of the short version ... disability in patients with depression, "which in the case of ... of the instrument." In Spain, more than 10% of ... is usually the first to screen an individual who feels ...
... by ESA,s Envisat satellite, shows the vast cloud of volcanic ... more than 1000 km away. Carried by winds high ... eruption of the Eyjafjallajoekull glacier in southwest Iceland has led ... with further disruption in northern Europe expected later today. The ...
Cached Biology News:Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 2It takes only 5 minutes to assess disability in patients with depression 2
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
Biology Products: